These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 32016694)

  • 1. The role of epsilon phenotype in brain glucose consumption in Alzheimer's disease.
    Ricci M; Chiaravalloti A; Martorana A; Koch G; De Lucia V; Barbagallo G; Schillaci O
    Ann Nucl Med; 2020 Apr; 34(4):254-262. PubMed ID: 32016694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
    Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O
    Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer's disease.
    Liguori C; Chiaravalloti A; Sancesario G; Stefani A; Sancesario GM; Mercuri NB; Schillaci O; Pierantozzi M
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2040-9. PubMed ID: 27221635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional correlates of t-Tau, p-Tau and Aβ₁₋₄₂ amyloid cerebrospinal fluid levels in Alzheimer's disease: a ¹⁸F-FDG PET/CT study.
    Chiaravalloti A; Martorana A; Koch G; Toniolo S; di Biagio D; di Pietro B; Schillaci O
    Nucl Med Commun; 2015 May; 36(5):461-8. PubMed ID: 25646706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional correlates of TSH, fT3 and fT4 in Alzheimer disease: a F-18 FDG PET/CT study.
    Chiaravalloti A; Ursini F; Fiorentini A; Barbagallo G; Martorana A; Koch G; Tavolozza M; Schillaci O
    Sci Rep; 2017 Jul; 7(1):6220. PubMed ID: 28740088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease.
    Haense C; Buerger K; Kalbe E; Drzezga A; Teipel SJ; Markiewicz P; Herholz K; Heiss WD; Hampel H
    Eur J Neurol; 2008 Nov; 15(11):1155-62. PubMed ID: 18803648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is cerebral glucose metabolism related to blood-brain barrier dysfunction and intrathecal IgG synthesis in Alzheimer disease?: A 18F-FDG PET/CT study.
    Chiaravalloti A; Fiorentini A; Francesco U; Martorana A; Koch G; Belli L; Toniolo S; Di Pietro B; Motta C; Schillaci O
    Medicine (Baltimore); 2016 Sep; 95(37):e4206. PubMed ID: 27631200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coupled Imaging with [
    Chiaravalloti A; Castellano AE; Ricci M; Barbagallo G; Sannino P; Ursini F; Karalis G; Schillaci O
    Mol Imaging Biol; 2018 Aug; 20(4):659-666. PubMed ID: 29404839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer's disease.
    Mosconi L; Nacmias B; Sorbi S; De Cristofaro MT; Fayazz M; Tedde A; Bracco L; Herholz K; Pupi A
    J Neurol Neurosurg Psychiatry; 2004 Mar; 75(3):370-6. PubMed ID: 14966149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical Localization and Dissociation between Glucose Uptake and Amyloid Deposition in Cognitively Normal APOE*E4 Homozygotic Elders Compared with Patients with Late-Onset Alzheimer's Disease.
    Pardo JV; Lee JT;
    eNeuro; 2018; 5(1):. PubMed ID: 29497704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain metabolic patterns in patients with suspected non-Alzheimer's pathophysiology (SNAP) and Alzheimer's disease (AD): is [
    Chiaravalloti A; Barbagallo G; Martorana A; Castellano AE; Ursini F; Schillaci O
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1796-1805. PubMed ID: 31201430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer's disease.
    Yakushev I; Muller MJ; Buchholz HG; Lang U; Rossmann H; Hampel H; Schreckenberger M; Fellgiebel A
    Curr Alzheimer Res; 2012 Feb; 9(2):241-7. PubMed ID: 22044023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How the cognitive reserve interacts with β-amyloid deposition in mitigating FDG metabolism: An observational study.
    Carapelle E; Serra L; Modoni S; Falcone M; Caltagirone C; Bozzali M; Specchio LM; Avolio C
    Medicine (Baltimore); 2017 Apr; 96(16):e5876. PubMed ID: 28422821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two distinct pathological substrates associated with MMSE-pentagons item deficit in DLB and AD.
    Beretta L; Caminiti SP; Santangelo R; Magnani G; Ferrari-Pellegrini F; Caffarra P; Perani D
    Neuropsychologia; 2019 Oct; 133():107174. PubMed ID: 31446008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and APO E4 medial temporal lobe dementias. The Oxford Project to Investigate Memory and Aging.
    Jobst KA; Barnetson LP; Shepstone BJ
    Int Psychogeriatr; 1997; 9 Suppl 1():191-222; discussion 247-52. PubMed ID: 9447442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints.
    Mosconi L; De Santi S; Brys M; Tsui WH; Pirraglia E; Glodzik-Sobanska L; Rich KE; Switalski R; Mehta PD; Pratico D; Zinkowski R; Blennow K; de Leon MJ
    Biol Psychiatry; 2008 Mar; 63(6):609-18. PubMed ID: 17720148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease.
    Drzezga A; Grimmer T; Henriksen G; Stangier I; Perneczky R; Diehl-Schmid J; Mathis CA; Klunk WE; Price J; DeKosky S; Wester HJ; Schwaiger M; Kurz A
    Neuroimage; 2008 Jan; 39(2):619-33. PubMed ID: 17962045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
    Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
    Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
    Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
    Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.